SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, development, and ...
SAN DIEGO, March 09, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, ...
Prometheus Biosciences contends that the current treatments for inflammatory bowel disease are inadequate, taking a “one-size-fits-all approach” that doesn’t account for biologic variation. The ...
- APOLLO-CD Phase 2a along with ARTEMIS-UC Phase 2 topline results expected in fourth quarter 2022 - - Final Phase 1a results for PRA023 in normal healthy volunteers expected in fourth quarter 2021- ...
SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development ...
-PRA023, an anti-TL1A mAb, on track to initiate Phase 2 study for Ulcerative Colitis and Phase 2a study for Crohn’s Disease in 3Q 2021- -Launched Prometheus Enroll360™, a global patient recruitment ...
- Topline results for ongoing Phase 2 clinical trial in ulcerative colitis and Phase 2a trial in Crohn’s disease expected in fourth quarter 2022 - - Phase 2 trial in Systemic Sclerosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback